{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:01:01Z","timestamp":1777510861987,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10067-018-4227-7","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T13:57:33Z","timestamp":1536242253000},"page":"3285-3296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4\u00a0years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial"],"prefix":"10.1007","volume":"37","author":[{"given":"J. A.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hoepken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Nurminen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,6]]},"reference":[{"issue":"suppl 2","key":"4227_CR1","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","volume":"64","author":"D Gladman","year":"2005","unstructured":"Gladman D, Antoni C, Mease P, Clegg D, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(suppl 2):ii14\u2013ii17","journal-title":"Ann Rheum Dis"},{"key":"4227_CR2","doi-asserted-by":"crossref","unstructured":"Kerschbaumer A, Fenzl KH, Erlacher L, Aletaha D (2016) An overview of psoriatic arthritis\u2013epidemiology, clinical features, pathophysiology and novel treatment targets. Wien Klin Wochenschr:1\u20135","DOI":"10.1007\/s00508-016-1111-9"},{"issue":"S11","key":"4227_CR3","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1002\/acr.20577","volume":"63","author":"PJ Mease","year":"2011","unstructured":"Mease PJ (2011) Measures of psoriatic arthritis: tender and swollen joint assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy\u2013Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken) 63(S11):S64\u2013S85","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"4227_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","volume":"45","author":"JA Husted","year":"2001","unstructured":"Husted JA, Gladman DD, Farewell VT, Cook RJ (2001) Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 45(2):151\u2013158","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"4227_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jaad.2005.10.008","volume":"54","author":"PJ Mease","year":"2006","unstructured":"Mease PJ, Menter MA (2006) Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 54(4):685\u2013704. https:\/\/doi.org\/10.1016\/j.jaad.2005.10.008","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"4227_CR6","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68(5):1060\u20131071","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"4227_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","volume":"73","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, van der Heijde D (2014) Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73(1):48\u201355. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203696","journal-title":"Ann Rheum Dis"},{"key":"4227_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/annrheumdis-2016-eular.3205","volume":"75","author":"P Mease","year":"2016","unstructured":"Mease P, Fleischmann R, Wollenhaupt J, Deodhar A, Gladman D, Hoepken B, Peterson L, van der Heijde D (2016) FRI0472 improvements in joint outcomes of psoriatic arthritis over 4 years of treatment with certolizumab pegol in patients with and without prior anti-TNF exposure. Ann Rheum Dis 75:609","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4227_CR9","doi-asserted-by":"publisher","first-page":"e000119","DOI":"10.1136\/rmdopen-2015-000119","volume":"1","author":"P Mease","year":"2015","unstructured":"Mease P, Deodhar A, Fleischmann R, Wollenhaupt J, Gladman D, Leszczy\u0144ski P, Vitek P, Turkiewicz A, Khraishi M, FitzGerald O, Landew\u00e9 R, de Longueville M, Hoepken B, Peterson L, van der Heijde D (2015) Effect of certolizumab pegol over 96\u00a0weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open 1(1):e000119. https:\/\/doi.org\/10.1136\/rmdopen-2015-000119","journal-title":"RMD Open"},{"key":"4227_CR10","unstructured":"EMA (2017) Summary of product characteristics (Cimzia). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001037\/WC500069763.pdf . Accessed 24 Apr 2018"},{"issue":"3","key":"4227_CR11","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjd.15665","volume":"177","author":"C Smith","year":"2017","unstructured":"Smith C, Jabbar-Lopez Z, Yiu Z, Bale T, Burden A, Coates L, Cruickshank M, Hadoke T, MacMahon E, Murphy R, Nelson-Piercy C (2017) British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol 177(3):628\u2013636","journal-title":"Br J Dermatol"},{"key":"4227_CR12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen J, Ramiro S, De Wit M, Cutolo M, Dougados M, Emery P, Landew\u00e9 R, Oliver S, Aletaha D (2016) European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75:499\u2013510","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 85","key":"4227_CR13","first-page":"113","volume":"32","author":"E Ferguson","year":"2014","unstructured":"Ferguson E, Coates L (2014) Optimisation of rheumatology indices: dactylitis and enthesitis in psoriatic arthritis. Clin Exp Rheumatol 32(Suppl 85):113\u2013117","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"4227_CR14","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS (2008) Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Care Res (Hoboken) 59(5):686\u2013691","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"4227_CR15","first-page":"123","volume":"34","author":"SE Cassell","year":"2007","unstructured":"Cassell SE, Bieber JD, Rich P, Tutuncu ZN, Lee SJ, Kalunian KC, Wu CW, Kavanaugh A (2007) The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 34(1):123\u2013129","journal-title":"J Rheumatol"},{"issue":"suppl 2","key":"4227_CR16","doi-asserted-by":"crossref","first-page":"ii61","DOI":"10.1136\/ard.2004.030809","volume":"64","author":"D Heijde van der","year":"2005","unstructured":"van der Heijde D, Sharp J, Wassenberg S, Gladman D (2005) Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 64(suppl 2):ii61\u2013ii64","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4227_CR17","first-page":"S14","volume":"23","author":"B Bruce","year":"2005","unstructured":"Bruce B, Fries J (2005) The health assessment questionnaire (HAQ). Clin Exp Rheumatol 23(5):S14","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"4227_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum (Munch) 23(2):137\u2013145","journal-title":"Arthritis Rheum (Munch)"},{"issue":"11","key":"4227_CR19","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.3899\/jrheum.110546","volume":"38","author":"PJ Mease","year":"2011","unstructured":"Mease PJ, Woolley JM, Bitman B, Wang BC, Globe DR, Singh A (2011) Minimally important difference of health assessment questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol 38(11):2461\u20132465. https:\/\/doi.org\/10.3899\/jrheum.110546","journal-title":"J Rheumatol"},{"key":"4227_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2013-203660","volume":"74","author":"VP Bykerk","year":"2015","unstructured":"Bykerk VP, Cush J, Winthrop K, Calabrese L, Lortholary O, De Longueville M, Van Vollenhoven R, Mariette X (2015) Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis 74:96\u2013103","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"4227_CR21","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1136\/annrheumdis-2016-eular.3192","volume":"75","author":"PJ Mease","year":"2016","unstructured":"Mease PJ, Fleischmann R, Wollenhaupt J, Deodhar A, Gladman D, Hoepken B, Peterson L, van der Heijde D (2016) FRI0471 certolizumab pegol for the treatment of psoriatic arthritis: 4-year outcomes from the rapid-Psa trial. Ann Rheum Dis 75(Suppl 2):608\u2013609. https:\/\/doi.org\/10.1136\/annrheumdis-2016-eular.3192","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4227_CR22","doi-asserted-by":"publisher","first-page":"e000582","DOI":"10.1136\/rmdopen-2017-000582","volume":"4","author":"D Heijde van der","year":"2018","unstructured":"van der Heijde D, Deodhar A, FitzGerald O, Fleischmann R, Gladman D, Gottlieb AB, Hoepken B, Bauer L, Irvin-Sellers O, Khraishi M (2018) 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open 4(1):e000582","journal-title":"RMD Open"},{"issue":"1","key":"4227_CR23","doi-asserted-by":"publisher","first-page":"e000181","DOI":"10.1136\/rmdopen-2015-000181","volume":"1","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, Collier DH, Saunders KC, Li G, Kremer JM, Greenberg JD (2015) Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open 1(1):e000181. https:\/\/doi.org\/10.1136\/rmdopen-2015-000181","journal-title":"RMD Open"},{"issue":"5","key":"4227_CR24","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58(5):826\u2013850","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"4227_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1590\/abd1806-4841.20153113","volume":"90","author":"PS Kurizky","year":"2015","unstructured":"Kurizky PS, Ferreira CC, Nogueira LSC, da Mota LMH (2015) Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding. An Bras Dermatol 90(3):367\u2013375. https:\/\/doi.org\/10.1590\/abd1806-4841.20153113","journal-title":"An Bras Dermatol"},{"issue":"9","key":"4227_CR26","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1093\/rheumatology\/kev404","volume":"55","author":"J Flint","year":"2016","unstructured":"Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K, Arthanari S, Cunningham J, Flanders L, Moore L (2016) BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding\u2014part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology 55(9):1693\u20131697","journal-title":"Rheumatology"},{"issue":"2","key":"4227_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jaad.2006.12.003","volume":"57","author":"M Papoutsaki","year":"2007","unstructured":"Papoutsaki M, Chimenti M-S, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S (2007) Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 57(2):269\u2013275. https:\/\/doi.org\/10.1016\/j.jaad.2006.12.003","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"4227_CR28","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1365-2133.2005.06648.x","volume":"153","author":"A Mastroianni","year":"2005","unstructured":"Mastroianni A, Minutilli E, Mussi A, Bordignon V, Trento E, D'Agosto G, Cordiali-Fei P, Berardesca E (2005) Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol 153(3):531\u2013536. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06648.x","journal-title":"Br J Dermatol"},{"issue":"4","key":"4227_CR29","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1159\/000354263","volume":"227","author":"MS Chimenti","year":"2013","unstructured":"Chimenti MS, Teoli M, Saraceno R, Dattola A, Ventura A, Chiricozzi A, Chiaramonte C, Perricone R, Chimenti S (2013) Golimumab in patients affected by moderate to severe psoriatic arthritis: an open-label study in thirty-two patients previously treated with other biologics. Dermatology 227(4):305\u2013310. https:\/\/doi.org\/10.1159\/000354263","journal-title":"Dermatology"},{"issue":"6","key":"4227_CR30","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3899\/jrheum.151290","volume":"43","author":"B Combe","year":"2016","unstructured":"Combe B, Behrens F, McHugh N, Brock F, Kerkmann U, Kola B, Gallo G (2016) Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: results from 2 clinical trials. J Rheumatol 43(6):1063\u20131067. https:\/\/doi.org\/10.3899\/jrheum.151290","journal-title":"J Rheumatol"},{"issue":"9227","key":"4227_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356(9227):385\u2013390","journal-title":"Lancet"},{"issue":"7","key":"4227_CR32","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"PJ Mease","year":"2004","unstructured":"Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheumatol 50(7):2264\u20132272","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"4227_CR33","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen Y-K, Doyle MK, Mendelsohn AM (2014) Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73(6):990\u2013999","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4227_CR34","first-page":"AB253","volume":"76","author":"J Walsh","year":"2017","unstructured":"Walsh J, Gottlieb AB, Hoepken B, Nurminen T, Mease PJ (2017) The efficacy of certolizumab pegol over 4 years in psoriatic arthritis patients with and without concomitant use of DMARDs. J Am Acad Dermatol 76(6):AB253 (Poster 5507)","journal-title":"J Am Acad Dermatol"},{"key":"4227_CR35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","volume":"77","author":"X Mariette","year":"2018","unstructured":"Mariette X, F\u00f6rger F, Abraham B, Flynn AD, Molt\u00f3 A, Flipo R-M, van Tubergen A, Shaughnessy L, Simpson J, Teil M, Helmer E, Wang M, Chakravarty EF (2018) Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 77:228\u2013233","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"4227_CR36","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1136\/annrheumdis-2017-211384","volume":"76","author":"ME Clowse","year":"2017","unstructured":"Clowse ME, F\u00f6rger F, Hwang C, Thorp J, Dolhain RJ, van Tubergen A, Shaughnessy L, Simpson J, Teil M, Toublanc N, Wang M, Hale TW (2017) Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis 76(11):1890\u20131896. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211384","journal-title":"Ann Rheum Dis"}],"updated-by":[{"DOI":"10.1007\/s10067-018-4311-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000}}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4227-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4227-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4227-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T22:55:49Z","timestamp":1751842549000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4227-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,6]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4227"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4227-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,6]]},"assertion":[{"value":"24 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The above article originally published with an error present in Discussion section and presented correctly in this article. The original article was corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JAW: Consultancies: Abbott, Celgene, UCB Pharma, and Novartis; ABG: Consultancies, speaking fees and honoraria: AbbVie, Janssen, Eli Lilly, Novartis, UCB Pharma, Allergan, Sienna, BMC, Sun Pharma; BH: Employee of UCB Pharma; TN: Employee of UCB Pharma; PJM: Research grants: AbbVie, Amgen, Bristol-Myers Squibb, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, UCB Pharma; Consultancies: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, UCB Pharma; Speakers\u2019 bureau: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Novartis, Pfizer, UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"UCB sponsored the study and the development of the manuscript and reviewed the text to ensure that from a UCB perspective, the data presented in the publication are scientifically, technically, and medically supportable, that they do not contain any information that has the potential to damage the intellectual property of UCB, and that the publication complies with applicable laws, regulations, guidelines, and good industry practice. The authors approved the final version to be published after critically revising the manuscript for important intellectual content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study sponsor information"}}]}}